S270: LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY
Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Vip Viprakasit(Siriraj Hospital), Antonio Piga, Ersi Voskaridou(Laiko General Hospital of Athens), A. Khélif(Hôpital Farhat Hached), Silverio Perrotta(University Hospital Foundation), Sadanand Vodala(Bristol-Myers Squibb (United States)), John B. Porter(Royal London Hospital), Frederik Lersch(Bristol-Myers Squibb (Switzerland)), Jeevan K. Shetty(Ente Ospedaliero Ospedali Galliera), Antonis Kattamis, Natalia Holot(Bristol-Myers Squibb (United States)), Kevin H.M. Kuo(University Health Network), Alì Taher(American University of Beirut Medical Center), O. Hermine(University Health Network), Thomas D. Coates(Children's Hospital of Los Angeles), Ashutosh Lal(Post Graduate Institute of Medical Education and Research), Dimana Miteva(Bristol-Myers Squibb (Switzerland)), J. Zhang(Bristol-Myers Squibb (United States))
Cited by 6
Related Papers
Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel
|Haematologica|2014|389
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia
|British Journal of Haematology|2000|292